Ozempic vs Mounjaro for Weight Loss: Which Works Better in 2026?

If you’re researching GLP-1 medications for weight loss, you’ve likely come across two names dominating the conversation: Ozempic (semaglutide) and Mounjaro (tirzepatide). Both are FDA-approved medications that help with weight loss — but they work differently, cost differently, and deliver different results.

This guide breaks down exactly how they compare, who each is best for, and — crucially — why most people end up choosing compounded semaglutide from a telehealth provider instead of either brand-name drug.

Ozempic vs Mounjaro: Quick Comparison

Feature	Ozempic (Semaglutide)	Mounjaro (Tirzepatide)
Drug Class	GLP-1 agonist	GLP-1 + GIP dual agonist
Brand-Name Cost	$900–$1,400/month	$1,000–$1,300/month
Compounded Version	Yes — widely available	Yes — available but fewer providers
Compounded Cost	$179–$349/month	$249–$449/month
Average Weight Loss	~15% body weight	~20-22% body weight
FDA Approval	Type 2 diabetes + weight (Wegovy)	Type 2 diabetes + weight (Zepbound)
Injection Frequency	Once weekly	Once weekly

How They Work: GLP-1 vs Dual Agonist

Ozempic (semaglutide) activates GLP-1 receptors in your body. GLP-1 is a hormone that slows stomach emptying, reduces appetite, and tells your brain you’re full. It also improves insulin sensitivity. The result: you eat less, feel satisfied sooner, and lose weight steadily.

Mounjaro (tirzepatide) activates both GLP-1 and GIP receptors simultaneously. GIP (glucose-dependent insulinotropic polypeptide) is another gut hormone that works synergistically with GLP-1 to amplify appetite suppression and metabolic effects. This dual action is why Mounjaro tends to produce slightly higher weight loss on average.

Does the Difference in Mechanism Actually Matter?

On paper, yes. In practice, individual response varies enormously. Some patients lose more on semaglutide than others lose on tirzepatide — and vice versa. Genetics, starting weight, diet, and activity all play a significant role. Don’t assume Mounjaro is automatically “better” for you personally just because average trial data shows higher numbers.

Weight Loss Results: What the Clinical Trials Show

The SURMOUNT-1 trial for tirzepatide showed average weight loss of 20.9% of body weight at the highest dose (15mg) over 72 weeks. The STEP-1 trial for semaglutide showed average weight loss of 14.9% of body weight at 2.4mg over 68 weeks.

That’s a meaningful difference — but context matters:

• Both trials used higher doses than most patients start on
• Both required lifestyle intervention alongside medication
• Real-world results are typically 10-15% lower than clinical trial outcomes
• Side effect profiles differ (more on this below)

Side Effects: Ozempic vs Mounjaro

Both medications share similar GI side effects, since both activate GLP-1 receptors. The most common include nausea, vomiting, diarrhea, and constipation — especially in the first 4-8 weeks as your body adjusts.

Mounjaro tends to cause slightly more nausea at equivalent weight-loss doses, because the dual mechanism creates a stronger appetite suppression signal. This can make dose titration feel more uncomfortable for some patients.

Both carry the same boxed warning about thyroid tumors (seen in rodent studies) and should be avoided if you have a personal or family history of medullary thyroid carcinoma or MEN 2.

The Real Question: Brand-Name or Compounded?

Here’s the part most comparison articles skip: the majority of people using GLP-1 medications in 2026 are not paying $1,000+/month for brand-name Ozempic or Mounjaro. They’re using compounded semaglutide or tirzepatide from telehealth providers — at 60-80% lower cost, with a legal prescription from a licensed doctor.

If cost is a factor (and for most people without insurance coverage, it is), the real comparison isn’t Ozempic vs Mounjaro. It’s:

• Compounded semaglutide at $179–$349/month vs Compounded tirzepatide at $249–$449/month
• Both from licensed telehealth providers with physician oversight
• Both use the same active molecules as the brand-name drugs

Which Compounded Option Should You Choose?

For most people starting a GLP-1 program, compounded semaglutide is the better starting point for three reasons:

• Lower starting cost — more accessible if you want to test your response before committing
• More providers and competition — more options means better pricing and service
• Well-established safety profile — semaglutide has been in use longer, with more real-world data

If you’ve already tried semaglutide without sufficient results, tirzepatide is worth exploring — particularly if your provider offers it at a comparable price point.

Best Providers for Compounded Semaglutide in 2026

We’ve reviewed and ranked the top GLP-1 telehealth providers offering compounded semaglutide. Our top picks:

• Brightmeds — Best overall value, starting at $199/month with physician supervision
• Medvi — Best for personalized support, $249/month
• TrimRx — Best clinical oversight, $289+/month
• Ahvina — Most affordable option, from $179/month

→ See our full ranked comparison of GLP-1 providers for 2026

Verdict: Which Is Better, Ozempic or Mounjaro?

If you have full insurance coverage for either brand-name drug: Mounjaro (tirzepatide) has a slight edge in average weight loss results, especially at higher doses. For patients who haven’t responded adequately to semaglutide, it’s a logical next step.

If you’re paying out of pocket — which most people are — compounded semaglutide wins on value. You get the same active molecule as Ozempic, with physician supervision, for 70-80% less than brand-name pricing. Start there, see how your body responds, and escalate to tirzepatide only if needed.

The bottom line: don’t let brand loyalty or marketing drive your GLP-1 decision. Let your doctor and your budget guide you to the right starting point.